Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC)

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 6, 2012, Pages 813-820

  Panteliadou, Marianthi ^a   Giatromanolaki, Alexandra ^a   Touloupidis, Stavros ^a   Destouni, Evagelia ^b   Tsoutsou, Pelagia G ^a   Pantelis, Panagiotis ^b   Abatzoglou, Ioannis ^a   Sismanidou, Kyriaki ^a   Koukourakis, Michael I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Acceleration; Amifostine; Bladder cancer; Hypofractionation; Radiotherapy

Indexed keywords

AMIFOSTINE; DOXORUBICIN; ONDANSETRON;

ADULT; AGED; ALGORITHM; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CLONOGENESIS; CONFORMAL HYPOFRACTIONATED ACCELERATED RADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; DYSURIA; FEMALE; FREQUENCY ANALYSIS; HEMATURIA; HUMAN; INCONTINENCE; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROCTITIS;

AGED; AMIFOSTINE; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHEMORADIOTHERAPY; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM STAGING; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY, CONFORMAL; URINARY BLADDER NEOPLASMS;

EID: 84870549766     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.09.001     Document Type: Article

References (32)

1. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2001, 20:3061-3071.
2. Sauer R., Birkenhake S., Kuhn R., et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998, 40:121-127.
3. Munro N.P., Sundaram S.K., Weston P.M., et al. A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys 2010, 77:119-124.
4. Tran E., Souhami L., Tanguay S., et al. Bladder conservation treatment in the elderly population: Results and prognostic factors of muscle-invasive bladder cancer. Am J Clin Oncol 2009, 32:333-337.
5. Kotwal S., Choudhury A., Johnston C., et al. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 2008, 70:456-463.
6. Chung P.W., Bristow R.G., Milosevic M.F., et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 2007, 25:303-309.
7. Rödel C., Weiss C., Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006, 24:5536-5544.
8. Maciejewski B., Majewski S. Dose fractionation and tumor repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991, 21:163-170.
9. Majewski W., Maciejewski B., Majewski S., et al. Clinical radiobiology of stage T2-T3 bladder cancer. Int J Radiat Oncol Biol Phys 2004, 60:60-70.
10. Moonen L., vd Voet H., de Nijs R., et al. Muscle-invasive bladder cancer treated with external beam radiation: Influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys 1998, 42:525-530.
11. Horwich A., Dearnaley D., Huddart R., et al. A randomized trial of accelerated radiotherapy for localized invasive bladder cancer. Radiother Oncol 2005, 75:34-43.
12. Chapman J.D., Gillespie C.J., Reuvers A.P., et al. The inactivation of Chinese Hamster cells by X-rays: The effect of chemical modifiers on single and double events. Radiat Res 1975, 64:365-375.
13. Pos F.J., Hart G., Schneider C., et al. Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose?. Int J Radiat Oncol Biol Phys 2006, 64:1168-1173.
14. Scholten A.N., Leer J.W., Collins C.D., et al. Hypofractionated radiotherapy for invasive bladder cancer. Radiother Oncol 1997, 43:163-169.
15. Jose C.C., Price A., Norman A., et al. Hypofractionated radiotherapy for patients with carcinoma of the bladder. Clin Oncol 1999, 11:330-333.
16. Kaufman D.S., Winter K.A., Shipley W.U., et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000, 5:471-476.
17. Koukourakis M.I., Tsolos C., Touloupidis S. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer. Urology 2007, 69:245-250.
18. Koukourakis M.I., Abatzoglou I., Sivridis L., et al. Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res 2006, 26:2437-2443.
19. LENT SOMA tables. Radiother Oncol 1995, 35:17-60. [No authors listed].
20. Panteliadou M., Touloupidis S., Giatromanolaki A., et al. Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC). Med Oncol 2010, in press.
21. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000, 48:7-16.
22. Arcangeli G., Saracino B., Gomellini S., et al. A prospective phase III randomized trial of hypofractionation vs. conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, in press.
23. Kalogeridi M.A., Kelekis N., Kouvaris J., et al. Accelerated hypofractionated radiotherapy schedules in breast cancer: A review of the current literature. Rev Recent Clin Trials 2009, 4:147-151.
24. Saunders M., Dische S., Barrett A., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) vs. conventional radiotherapy in non-small-cell lung cancer: A randomized multicenter trial. CHART Steering Committee Lancet 1997, 350:161-165.
25. Cowan R.A., McBain C.A., Ryder W.D., et al. Radiotherapy for muscle-invasive carcinoma of the bladder: Results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59:197-207.
26. Athanassiou H., Antonadou D., Coliarakis N., et al. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: Results of a randomized trial. Int J Radiat Oncol Biol Phys 2003, 56:1154-1160. Oncology Hellenic Group.
27. Cassatt D.R., Fazenbaker C.A., Kifle G., et al. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Oncol Biol Phys 2003, 57:794-802.
28. Pos F.J., van Tienhoven G., Hulshof M.C., et al. Concomitant boost radiotherapy for muscle invasive bladder cancer. Radiother Oncol 2003, 68:75-78.
29. Hagan M.P., Winter K.A., Kaufman D.S., et al. RTOG 97-06: Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003, 57:665-672.
30. Koukourakis M.I. Amifostine: Is there evidence of tumor protection?. Semin Oncol 2003, 30:18-30.
31. Grdina D.J., Kataoka Y., Murley J.S., et al. Inhibition of spontaneous metastases formation by amifostine. Int J Cancer 2002, 97:135-141.
32. Koukourakis M.I., Ktenidou-Kartali S., Bourikas G., et al. Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells in breast cancer patients. Cancer Immunol Immunother 2003, 52:127-131.